FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295027368> ?p ?o ?g. }

• W4295027368 abstract "The efficacy of immune checkpoint inhibitors (ICIs) in pretreated EGFR-mutated non-small cell lung cancer (NSCLC) patients is controversial. We conducted this multicenter retrospective study to examine the efficacy of ICIs in a real world setting.We collected 116 consecutive NSCLC patients with sensitive EGFR mutations who received ICIs alone or in combination after failure to respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs), and 99 patients were included for final analysis. The impacts of ICIs on the patients' objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were assessed. The relationships between outcomes and clinical characteristics were analyzed.The ORR in patients with target lesions was 31.25% (95% CI: 22.18-41.52), and the DCR in all patients was 65.66% (95% CI: 55.44-74.91). The overall median PFS was 5.0 months (95% CI: 3.0-6.6), and the median OS was 15.9 months (95% CI: 10.8-23.8). The outcomes were better in patients receiving combination therapy with ECOG scores of 0-1 and no more than 2 lines of prior therapy, with a median PFS of 7.4 months (95% CI: 3.0-13.3) and a median OS of 29.0 months (95% CI: 11.7-NE). Primary EGFR mutation type and treatment mode were found to have a notable impact on clinical outcomes. Both median PFS and OS in patients with EGFR L858R mutation were significantly shorter than those in patients with EGFR exon 19 deletion (19del) (PFS: 2.5 versus 6.7 months, HR: 1.80, log-rank P=0.011; OS: 9.8 versus 26.9 months, HR: 2.48, log-rank P=0.002). Patients receiving combination therapy had notably longer median PFS and OS than those receiving monotherapy (PFS: 5.2 versus 3.0 months, HR: 0.54, log-rank P=0.020; OS: 19.0 versus 7.4 months, HR: 0.46, log-rank P=0.009).Our study suggests that ICI-based combination therapy is a potential strategy for EGFR-mutated NSCLC patients after EGFR-TKI failure. The efficacy may differ according to EGFR subtypes." @default.
• W4295027368 created "2022-09-09" @default.
• W4295027368 creator A5012647424 @default.
• W4295027368 creator A5015452019 @default.
• W4295027368 creator A5017298596 @default.
• W4295027368 creator A5022715798 @default.
• W4295027368 creator A5042174429 @default.
• W4295027368 creator A5043778112 @default.
• W4295027368 creator A5055910967 @default.
• W4295027368 creator A5059941852 @default.
• W4295027368 creator A5084713092 @default.
• W4295027368 creator A5086231834 @default.
• W4295027368 creator A5089067250 @default.
• W4295027368 date "2022-09-09" @default.
• W4295027368 modified "2023-09-22" @default.
• W4295027368 title "The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study" @default.
• W4295027368 cites W2088270805 @default.
• W4295027368 cites W2104347254 @default.
• W4295027368 cites W2125665528 @default.
• W4295027368 cites W2130256619 @default.
• W4295027368 cites W2132870547 @default.
• W4295027368 cites W2147592245 @default.
• W4295027368 cites W2198093519 @default.
• W4295027368 cites W2293531514 @default.
• W4295027368 cites W2538232731 @default.
• W4295027368 cites W2560367415 @default.
• W4295027368 cites W2560717039 @default.
• W4295027368 cites W2569357796 @default.
• W4295027368 cites W2572174216 @default.
• W4295027368 cites W2593630992 @default.
• W4295027368 cites W2737044461 @default.
• W4295027368 cites W2774645469 @default.
• W4295027368 cites W2791290180 @default.
• W4295027368 cites W2795708883 @default.
• W4295027368 cites W2883256340 @default.
• W4295027368 cites W2891760302 @default.
• W4295027368 cites W2898712957 @default.
• W4295027368 cites W2944860885 @default.
• W4295027368 cites W2946166987 @default.
• W4295027368 cites W2991567947 @default.
• W4295027368 cites W2992931937 @default.
• W4295027368 cites W3000415041 @default.
• W4295027368 cites W3132598929 @default.
• W4295027368 cites W3204380660 @default.
• W4295027368 cites W3205552647 @default.
• W4295027368 cites W4205124506 @default.
• W4295027368 cites W4213298499 @default.
• W4295027368 cites W4223622421 @default.
• W4295027368 cites W4242460399 @default.
• W4295027368 cites W4284966850 @default.
• W4295027368 doi "https://doi.org/10.3389/fimmu.2022.975246" @default.
• W4295027368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36159795" @default.
• W4295027368 hasPublicationYear "2022" @default.
• W4295027368 type Work @default.
• W4295027368 citedByCount "3" @default.
• W4295027368 countsByYear W42950273682023 @default.
• W4295027368 crossrefType "journal-article" @default.
• W4295027368 hasAuthorship W4295027368A5012647424 @default.
• W4295027368 hasAuthorship W4295027368A5015452019 @default.
• W4295027368 hasAuthorship W4295027368A5017298596 @default.
• W4295027368 hasAuthorship W4295027368A5022715798 @default.
• W4295027368 hasAuthorship W4295027368A5042174429 @default.
• W4295027368 hasAuthorship W4295027368A5043778112 @default.
• W4295027368 hasAuthorship W4295027368A5055910967 @default.
• W4295027368 hasAuthorship W4295027368A5059941852 @default.
• W4295027368 hasAuthorship W4295027368A5084713092 @default.
• W4295027368 hasAuthorship W4295027368A5086231834 @default.
• W4295027368 hasAuthorship W4295027368A5089067250 @default.
• W4295027368 hasBestOaLocation W42950273681 @default.
• W4295027368 hasConcept C126322002 @default.
• W4295027368 hasConcept C143998085 @default.
• W4295027368 hasConcept C167135981 @default.
• W4295027368 hasConcept C2776256026 @default.
• W4295027368 hasConcept C2776694085 @default.
• W4295027368 hasConcept C2778822529 @default.
• W4295027368 hasConcept C2780739268 @default.
• W4295027368 hasConcept C71924100 @default.
• W4295027368 hasConceptScore W4295027368C126322002 @default.
• W4295027368 hasConceptScore W4295027368C143998085 @default.
• W4295027368 hasConceptScore W4295027368C167135981 @default.
• W4295027368 hasConceptScore W4295027368C2776256026 @default.
• W4295027368 hasConceptScore W4295027368C2776694085 @default.
• W4295027368 hasConceptScore W4295027368C2778822529 @default.
• W4295027368 hasConceptScore W4295027368C2780739268 @default.
• W4295027368 hasConceptScore W4295027368C71924100 @default.
• W4295027368 hasLocation W42950273681 @default.
• W4295027368 hasLocation W42950273682 @default.
• W4295027368 hasLocation W42950273683 @default.
• W4295027368 hasLocation W42950273684 @default.
• W4295027368 hasOpenAccess W4295027368 @default.
• W4295027368 hasPrimaryLocation W42950273681 @default.
• W4295027368 hasRelatedWork W1967103478 @default.
• W4295027368 hasRelatedWork W2032912323 @default.
• W4295027368 hasRelatedWork W2372561159 @default.
• W4295027368 hasRelatedWork W2375344515 @default.
• W4295027368 hasRelatedWork W2390152934 @default.
• W4295027368 hasRelatedWork W2516942920 @default.
• W4295027368 hasRelatedWork W2723438097 @default.
• W4295027368 hasRelatedWork W3197633853 @default.
• W4295027368 hasRelatedWork W3208090289 @default.

• next